Clinical trialPolish biotech JPP Biologics reports positive Phase I data for first-in-class biologic for immune diseasesJJP Biologics has announced positive top-line results from a Phase I clinical trial of JJP-1212, its first-in-class anti-CD89 antagonist being developed for IgA-mediated inflammatory diseases. The data … more ➔
Genentech Corp. / RocheCollaborationAmgen selects German Disco Pharma to collaborate in multi-million-dollar dealThe new year at Cologne-based Disco Pharma has begun much as the old one ended: with a headline-grabbing announcement. Just weeks after closing a sizeable financing round, the company has now unveiled … more ➔
M&AAmgen acquires Dark Blue Therapeutics for up to $840 millionAmgen has agreed to acquire Dark Blue Therapeutics in a deal valued at up to $840 million, as the biopharmaceutical company continues to build out its early-stage oncology pipeline. The specific breakdown … more ➔
Photo from Shawn Day on Unsplash Drug developmentLoQus23 moves Huntington’s disease candidate into developmentUK-based biotech LoQus23 Therapeutics is advancing an oral small molecule targeting a fundamental genetic process in Huntington’s disease, a rare neurodegenerative disorder. more ➔
ManagementWith Vyvgart established, argenx looks beyond its founder CEOThe Dutch biotech argenx has announced a planned leadership transition to be effective in May after its annual shareholder meeting. Tim Van Hauwermeiren, co-founder and long-time Chief Executive Officer, … more ➔
R&D collaborationsServier and Insilico sign an $888 million AI oncology discovery dealOn January 4, the French pharma group Servier and the AI drug discovery Insilico Medicine announced a collaboration worth up to $888 million. Insilico will receive up to $32 million from Servier for … more ➔
IQVIAObesityFDA approves globally first obesity pillFDA approves Novo Nordisk’s first oral GLP-1 pill Wegovy for obesity, offering an injection-free option and improving long-term treatment adherence. more ➔
White HouseUS Pharma PricesNine Big Pharma to cut US drug prices in Most-favoured Nations dealsNine pharma giants will cut US drug prices up to 90 % via TrumpRx and direct channels, following previous Pfizer and AstraZeneca MFN deals. more ➔
ClarivateUS Biosecure ActTrump Administration tables new version of Biosecure ActThe Trump administration has tabled a new Biosecure Act, prompting industry concern over oversight shift, regulatory uncertainty and need for stronger US biotech strategy. more ➔
H. Zell - wikipedia.orgagri-biotechEU committee approves New Plant Breeding (NGT) techniquesOn Friday, the EU committee of Permanent Representatives of EU Member States backed the deregulation of new genomic plant breeding techniques, easing regulation for NGT1 crops. more ➔
Genentech Corp. / Roche
Photo from Shawn Day on Unsplash 
IQVIA
White House
Clarivate
H. Zell - wikipedia.org